- Home
- RNAC
as 06-20-2025 3:41pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 242.4M | IPO Year: | 2016 |
| Target Price: | $41.25 | AVG Volume (30 days): | 65.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.46 - $29.65 | Next Earning Date: | 08-07-2025 |
| Revenue: | $34,173,000 | Revenue Growth: | 31.91% |
| Revenue Growth (this year): | -90.89% | Revenue Growth (next year): | -87.05% |
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Apr 9 '25 | Buy | $10.30 | 149,075 | $1,522,517.04 | 8,628,667 |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
22 days ago
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
GlobeNewswire
a month ago
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Simply Wall St.
a month ago
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Simply Wall St.
a month ago
Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations
GlobeNewswire
a month ago
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
2 months ago
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.